A Study to Assess Electrocardiogram Results in Healthy Volunteers Receiving Canagliflozin (JNJ-28431754)
Status:
Completed
Trial end date:
2008-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the effect of canagliflozin (JNJ-28431754) on
electrocardiogram results (recordings of the electrical activity of the heart) in healthy
volunteers after a single therapeutic dose (300 mg) and a single supra-therapeutic dose (4
times higher [1,200 mg] than the anticipated therapeutic dose of 300 mg). The safety and
tolerability of canagliflozin will also be assessed.
Phase:
Phase 1
Details
Lead Sponsor:
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Treatments:
Canagliflozin Fluoroquinolones Moxifloxacin Norgestimate, ethinyl estradiol drug combination